Richard G Moore
Overview
Explore the profile of Richard G Moore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
3361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eskander R, Sill M, Beffa L, Moore R, Hope J, Musa F, et al.
Nat Med
. 2025 Mar;
PMID: 40044930
Historically, the treatment of patients with advanced stage or recurrent endometrial cancer included paclitaxel plus carboplatin. Immunotherapy in combination with chemotherapy resulted in improved clinical outcomes in several solid tumors....
2.
Kim K, Khazan N, McDowell J, Snyder C, Miller J, Singh R, et al.
PLoS One
. 2024 Dec;
19(12):e0314564.
PMID: 39621651
Ovarian cancer is the leading cause of death among gynecologic malignancies. Despite recent advancements in targeted therapies such as PARP inhibitors, recurrence is common and frequently resistant to existing therapies....
3.
Marth C, Moore R, Bidzinski M, Pignata S, Ayhan A, Rubio M, et al.
J Clin Oncol
. 2024 Nov;
43(9):1083-1100.
PMID: 39591551
Purpose: Lenvatinib plus pembrolizumab (len + pembro) significantly improved progression-free survival (PFS) and overall survival (OS) versus chemotherapy in previously treated advanced or recurrent endometrial cancer (aEC) in the phase...
4.
Lee J, Brady M, Miller A, Moore R, MacKay H, McNally L, et al.
J Clin Oncol
. 2024 Oct;
42(36):4305-4316.
PMID: 39361946
Purpose: We assessed the efficacy of cediranib, olaparib, and cediranib/olaparib compared with standard-of-care chemotherapy (SOC) in platinum-resistant or platinum-refractory epithelial ovarian cancer (PROC). Patients And Methods: NRG-GY005 is an open-label,...
5.
Ciccioli M, Kim K, Khazan N, Khoury J, Cooke M, Miller M, et al.
J Exp Clin Cancer Res
. 2024 Aug;
43(1):240.
PMID: 39169412
Circulating Tumor Cells (CTCs) may serve as a non-invasive source of tumor material to investigate an individual's disease in real-time. The Parsortix PC1 System, the first FDA-cleared medical device for...
6.
Graybill W, Pardo Burdalo B, OMalley D, Vergote I, Monk B, Auranen A, et al.
Int J Gynecol Cancer
. 2024 Jul;
34(7):1041-1050.
PMID: 38950925
Objective: To identify characteristics associated with long-term progression-free survival (≥2 years) in patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in the phase III PRIMA/ENGOT-OV26/GOG-3012 study. Methods:...
7.
Sahasrabudhe D, Liesveld J, Minhajuddin M, Singh N, Nath S, Kumar V, et al.
Sci Rep
. 2024 Jun;
14(1):12868.
PMID: 38834690
Acute myeloid leukemia (AML) is fatal in the majority of adults. Identification of new therapeutic targets and their pharmacologic modulators are needed to improve outcomes. Previous studies had shown that...
8.
Valabrega G, Pothuri B, Oaknin A, Graybill W, Sanchez A, McCormick C, et al.
Gynecol Oncol
. 2024 Jun;
187:128-138.
PMID: 38833992
Objective: To evaluate the impact of age on the efficacy and safety of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer with a complete/partial response to...
9.
Campbell E, Campbell T, Culakova E, Blanchard L, Wixom N, Guido J, et al.
Breast Cancer Res Treat
. 2024 Mar;
206(2):273-283.
PMID: 38553649
Purpose: Quality of life (QOL) is among the most important outcomes for women with metastatic breast cancer (MBC), and it predicts survival. QOL is negatively impacted by cognitive impairment, fatigue,...
10.
Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick C, et al.
Future Oncol
. 2024 Mar;
20(22):1531-1544.
PMID: 38501262
No abstract available.